Metformin is a first-line drug for the treatment of individuals with type 2 diabetes, yet its precise mechanism of action remains unclear. Metformin exerts its antihyperglycemic action primarily through lowering hepatic glucose production (HGP). This suppression is thought to be mediated through inhibition of mitochondrial respiratory complex I, and thus elevation of 5′ -adenosine monophosphate (AMP) levels and the activation of AMP-activated protein kinase (AMPK), though this proposition has been challenged given results in mice lacking hepatic AMPK. Here we report that the AMP-inhibited enzyme fructose-1,6-bisphosphatase-1 (FBP1), a rate-controlling enzyme in gluconeogenesis, functions as a major contributor to the therapeutic action of metformin. We identified a point mutation in FBP1 that renders it insensitive to AMP while sparing regulation by fructose-2,6-bisphosphate (F-2,6-P 2 ), and knock-in (KI) of this mutant in mice significantly reduces their response to metformin treatment. We observe this during a metformin tolerance test and in a metformin-euglycemic clamp that we have developed. The antihyperglycemic effect of metformin in high-fat diet-fed diabetic FBP1-KI mice was also significantly blunted compared to wild-type controls. Collectively, we show a new mechanism of action for metformin and provide further evidence that molecular targeting of FBP1 can have antihyperglycemic effects.
D iabetes is characterized by impaired glucose homeostasis partly due to abnormally elevated HGP. The biguanide drug metformin (N,N-dimethylbiguanide) works principally through inhibition of HGP, although enhanced glucose disposal has also been reported in some studies 1 . It is widely accepted that metformin inhibits mitochondrial respiration through complex I [2] [3] [4] , reducing hepatocellular energy charge. A previous study examined whether AMPK activation is responsible for the therapeutic effects of metformin; the reported data support a mechanism involving AMPK-dependent inhibition of HGP and lipogenesis 5 , although an inhibitor of questionable selectivity was used in the study 6 . Indeed, a recent study has demonstrated that inhibitory phosphorylation of acetyl-CoA carboxylase (ACC) by AMPK plays an important role in metformin-induced improvements in insulin action by maintaining hepatic lipid homeostasis 7 . However, the importance of AMPK in metformin action on HGP has been challenged in experiments using mice lacking hepatic AMPK 8 . Recent studies report that metformin inhibits HGP through hepatic AMPK-independent mechanisms, either by attenuating the ability of glucagon to increase 3′ ,5′ -cyclic adenosine monophosphate (cAMP) levels and promote HGP 9 or through direct inhibition of mitochondrial glycerol-3-phosphate dehydrogenase and the subsequent increase in cytosolic free [NADH]:[NAD + ], leading to impaired utilization of lactate for gluconeogenesis 10 . These findings suggest that the underlying mechanisms responsible for the HGP-and glucose-lowering effects of metformin in diabetes may not be explained by any single target or pathway. Interestingly, a widely used pharmacological AMPK activator, 5-aminoimidazole-4-carboxamide-1-β -D-ribofuranoside (AICAR), an AMP mimetic, profoundly suppressed glucose output in hepatocytes lacking AMPK 8, 11 , indicating AMP per se, but not AMPK, plays a vital role in suppressing HGP. Similarly, a tight correlation between the magnitude of increase in [AMP]:[ATP] and inhibition of glucose output in hepatocytes has been noted 8 .
Given that the anabolic process of gluconeogenesis is energetically costly, hepatocytes must balance this energy demand with production, thereby maintaining energy homeostasis. Hepatocytes are equipped with a mechanism to control the rate of hepatic gluconeogenesis in response to energy status, and FBP1 (Braunschweig Enzyme Databse (BRENDA) entry: EC 3.1.3.11) has long been recognized as a key component 12 . FBP1 catalyzes the irreversible hydrolysis of fructose-1,6-bisphosphate (F-1,6-P 2 ) to fructose-6-phosphate (F6P) and inorganic phosphate (P i ) in the presence of divalent cations. FBP1 is a key rate-controlling enzyme in the gluconeogenic pathway, and individuals with FBP1 deficiency present with hypoglycemia and metabolic acidosis due to impaired gluconeogenesis 13 . FBP1 activity is regulated synergistically by the allosteric inhibitors AMP and F-2,6-P 2 . AMP noncompetitively inhibits FBP1 by binding to a unique allosteric site, whereas F-2,6-P 2 binds to the active site in competition with F-1,6-P 2 . Although levels of F-2,6-P 2 are largely under hormonal control, AMP concentration is a function of the energy status of the tissue and contributes to autoregulation of gluconeogenesis. We hypothesized that acute inhibition of gluconeogenesis by metformin is due to inhibition of FBP1, secondary to increases in the AMP concentration through reducing hepatocellular energy charge. Interestingly, inhibition by 5-inosine monophosphate (IMP) was unaffected by the mutation. Although IMP is not a physiologically relevant ligand for FBP1, this highlights that the substitution has not disrupted the function of the allosteric pocket but has merely reduced the affinity for AMP beyond the physiological range. Indeed, titration with the fluorescent AMP analog TNP-AMP demonstrated a significant reduction in binding affinity ( Supplementary  Table 1 ), which was further confirmed by the inability of FBP1-G27P to bind AMP immobilized on a solid support ( Supplementary  Fig. 1c ). Finally, we assessed thermal stability as an indicator of the stability of the folded state of the mutant ( Supplementary Fig. 1d ). Melting temperature (T m ) was essentially unaffected by the p.G27P substitution (69.2 ± 0.2 °C versus 68.6 ± 0.2 °C). Interestingly, saturating AMP concentration did not shift T m for WT protein but substantially reduced resting fluorescence at ambient temperature, revealing a clear biphasic transition from the more closed tense (T) state upon heating. As expected, this was not observed for FBP1-G27P, but the stabilizing effect of F-1,6-P 2 was conserved.
Generation and characterization of an AMP-insensitive FBP1-G27P-KI mouse model. To establish whether AMP-mediated inhibition of FBP1 activity contributes to the antihyperglycemic action of metformin in vivo, we generated an FBP1-G27P-KI mouse model in which the codon for glycine 27 of Fbp1 was modified to encode proline (Fig. 1d ). FBP1 is predominantly expressed in liver and kidney and to a much lesser extent in testes and small intestine ( Supplementary Fig. 2a ). Although expression of FBP1 in islets has been reported 17 , in our study it was undetectable using a highly specific antibody ( Supplementary Fig. 2a ). We confirmed that expression and activity of FBP1 were comparable between homozygous FBP1-G27P-KI (KI mice) and control WT mice in liver and kidney, although FBP1 expression in KI mice was modestly higher in small intestine and lower in testes compared to WT mice ( Fig. 1e and Supplementary Fig. 2b,c) . Assayed in crude liver extracts, AMP exhibited an IC 50 for FBP1-G27P inhibition that was > 400-fold higher than that for WT FBP1 (Fig. 1e ), which is far beyond the physiological range of cellular AMP concentrations 18 .
KI mice were born at the expected Mendelian frequency and displayed similar body weight and growth curves (data not shown), food intake and respiratory exchange ratio as well as locomotor activity to that of WT mice ( Supplementary Fig. 3a-f ). Relative to WT, KI mice exhibited similar blood glucose, plasma insulin, glucagon and leptin levels as well as hepatic glycogen content under fasted and refed (4 h ad libitum food access following overnight fast) conditions ( Fig. 2a-e ). KI mice also displayed normal blood glucose tolerance ( Fig. 2f ) and gluconeogenic capacity, assessed by the pyruvate-tolerance test (Fig. 2g ). In accordance with these observations, immunoblot analysis revealed comparable expression of major metabolic proteins involved in hepatic glucose metabolism (for example, GLUT2, glucokinase (GCK) and its regulator protein GCKR, hexokinase 1 (HXK1), phosphofructokinase (PFKL), 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB1), FBP1 and glucose-6-phosphate dehydrogenase (G6PD)), glycogen metabolism (for example, glycogen synthase (GYS2) and glycogen phosphorylase (PYGL)) and gluconeogenesis (for example, catalytic and transporter subunit of glucose-6 phosphatase (G6PC/T), cytosolic/mitochondrial isoforms of phosphoenolpyruvate carboxykinase (PEPCK-C/M), pyruvate carboxylase (PC) and pyruvate kinase (PKLR)) as well as the major metformin transporter organic cation transporter 1 (OCT1) between WT and KI mice under fasted and refed conditions ( Fig. 2h and Supplementary Fig. 4 ). Moreover, activities of the major gluconeogenic and glycolytic enzymes were similar between WT and KI mice under both fasted and refed conditions ( Supplementary Fig. 5a -i). At the transcript level, mRNA expression levels of genes involved in gluconeogenesis (Pck1, Pparg1c and Foxo1a) and lipogenesis (Fasn) were similar between WT and KI mice ( Supplementary Fig. 5j-m) . Conversely, the G6pc mRNA level was significantly lower in KI mice under both fasted and refed conditions ( Supplementary Fig. 5n ), although this did not translate into a difference at the protein level ( Fig. 2h and Supplementary Fig. 4b ) or in activity ( Supplementary Fig. 5b ). Similarly, Gck mRNA was higher in refed KI mice ( Supplementary  Fig. 5o ); however, again, protein levels and enzyme activity were unchanged (Supplementary Fig. 4d and Supplementary Fig. 5a ). Phosphorylation states of hormone-and/or nutrient-regulated proteins showed the anticipated changes in response to refeeding, such as increased phosphorylation of p70S6K and S6, downstream components of mTOR, and decreased phosphorylation of GYS2 and PYGL as well as PFKFB1, the enzyme that synthesizes F-2,6-P 2 and a major substrate of cAMP-dependent protein kinase ( Fig. 2h and Supplementary Fig. 4 ). Hepatic lactate and pyruvate are the major three-carbon precursors for gluconeogenesis, and their levels were unchanged between WT and KI mice under both fasted and refed conditions ( Supplementary Table 2 ). Likewise, hepatic glucose and G6P concentrations were similar between WT and KI mice. Furthermore, there was no difference in the levels of F6P and F-1,6-P 2 , the substrate and product of FBP1, respectively 
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(Supplementary Table 2 ). The loss of regulation by AMP of FBP1 does not have an apparent impact on gluconeogenic flux under normal conditions. The mutant does remain sensitive to hormonal regulation by F-2,6-P 2 , of which the levels were also unchanged between WT and KI mice. Hepatic adenine nucleotide levels and energy charge were similar in fasted and refed conditions and were comparable between WT and KI mice ( Supplementary Table 3 ).
Taken together, these results demonstrated that KI mice possess normal hepatic energy and metabolic homeostasis as well as wholebody glucose homeostasis.
FBP1-G27P-KI mice are resistant to the hypoglycemic action of AMP mimetic compounds. Prior to testing the effect of metformin, we wanted to confirm whether KI mice are resistant to AMPmediated lowering of blood glucose in vivo. For this purpose, we initially used the AMP mimetic FBPase inhibitor MB06322 (ref. 19 ), the prodrug of MB05032 ( Fig. 3a and Supplementary Table 1 ). We observed that recombinant mouse FBP1 was approximately twofold less sensitive to MB05032 compared to rat FBP1 in vitro, whereas sensitivity to AMP was comparable between the two species ( Fig. 3b ). As all available preclinical data were only obtained from rats, we took the species difference in drug response into account, and 75 mg of MB06322 per kg body weight (mg kg -1 ) was administered intraperi-toneally (i.p.) to WT and KI mice. In WT mice, MB06322 treatment resulted in a robust and sustained decrease (~40% at 2-3 h post injection) in blood glucose levels ( Fig. 3c ), which was accompanied by an increase in blood lactate levels ( Fig. 3d ). In contrast, even though plasma concentration of the drug was comparable between genotypes ( Fig. 3e ), MB06322 had no significant effect on both blood glucose and lactate concentration in KI mice ( Fig. 3f ,g). We next sought to determine whether the well-documented hypoglycemic effect of AICAR 20 , which is converted intracellularly to the AMPmimetic ZMP (Fig. 4a ), is mediated through ZMP-dependent inhibition of FBP1 in vivo. Administration of AICAR (250 mg kg -1 , i.p.) resulted in a profound (up to ~60%) decrease in blood glucose levels in WT ( Fig. 4b ) but not KI ( Fig. 4c ) mice, whereas the plasma concentration of AICAR was similar between the two groups ( Fig. 4d ). Consistent with the results observed with MB06322, AICAR induced a marked increase in blood lactate levels in WT mice ( Fig. 4e ), but the increase was only modest in KI mice ( Fig. 4f ). Plasma glucagon levels were increased in AICAR-treated WT ( Fig. 4g ) but not KI ( Fig. 4h ) mice, most likely to counteract the rapid induction of hypoglycemia ( Fig. 4b ). There was no significant change in plasma insulin levels ( Fig. 4i ,j). As anticipated, AICAR robustly stimulated phosphorylation of liver AMPK and its bona fide substrate ACC in both WT and KI mice ( Fig. 4k ,l). This was accompanied by a 
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profound increase in liver ZMP and ZTP concentrations in both groups of mice (Supplementary Table 4 ). As previously reported in both intact animals 11, 20 and isolated hepatocytes 12, 21 , AICAR administration in WT mice resulted in a substantial decrease in the total adenine nucleotide pool (Supplementary Table 4 ). The conversion of AICAR to ZMP by adenosine kinase consumes ATP and acts as a trap for phosphate, similar to the metabolic consequences of a large fructose bolus. This effect is further enhanced by substantial substrate cycling between AICAR and ZMP due to dephosphorylation by 5′ -nucleotidase 22 . This leads to depletion of P i , resulting in deinhibition of AMP deaminase and the loss of adenine nucleotides. However, this mechanism cannot be fully responsible, as AICAR had minimal effect on adenine nucleotides in KI mice despite similar accumulation of ZMP ( Supplementary Table 4 ). Furthermore, AICAR was previously observed to have no significant effect on ATP levels in fed mice 20 . The common factor here is likely the absence of an acute glucose-lowering effect and inhibition of a high gluconeogenic flux, which leads to the accumulation of additional phosphorylated species (for example, F-1,6-P 2 and the triose phosphates) as additional sinks for P i (data not shown). Interestingly, AICAR treatment lead to a similar increase in hepatic NAD + in both WT and KI mice ( Supplementary Table 4 ), which was likely due to AMPK-dependent inhibition of fatty acid synthesis and the subsequent increase in β -oxidation. In skeletal muscle, AICAR failed to increase AMPKα T172 phosphorylation and activity in both WT and KI mice ( Supplementary  Fig. 6a -c), although it enhanced phosphorylation of ACC and TBC1 domain family member 1 (TBC1D1), most likely via ZMPdependent allosteric activation of AMPK ( Supplementary Fig.  6d ,e). Notably, AICAR was unable to stimulate phosphorylation of RAPTOR, which is a marker of more robust AMPK activation 23 ( Supplementary Fig. 6f ). Indeed, ZMP concentration and [ZMP]:[ATP] ratio in skeletal muscle were > 50-fold and > 150-fold less, respectively, than that detected in liver following AICAR treatment, a consequence of the considerable first-pass metabolism of AICAR and low plasma concentration (Supplementary Table 4 and Supplementary Fig. 6g ). Thus, it is presumed that the magnitude of AMPK activation following AICAR treatment in skeletal muscle was below the threshold to cause lowering of blood glucose in KI mice through promoting glucose uptake in this tissue. Collectively, or KI (f,g) mice, and blood glucose was monitored at the indicated intervals for 3 h (c,f). Lactate was measured just before drug administration and at t = 120 min using a lactate meter (d,g). Plasma levels of MB05032 were assayed from blood samples drawn at the end of the protocol (t = 180 min) (e). Results represent mean ± s.e.m.; n = 4 or 5 mice per treatment group. *P < 0.05 (vehicle versus MB06322). Statistical significance was determined using the unpaired, two-tailed Student's t-test and an alpha level of 0.05.
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using two AMP mimetic drugs, we have confirmed that the FBP1-G27P-KI model is suitable to investigate the effect of an AMPelevating agent (i.e., metformin) on blood glucose in vivo.
FBP1-G27P-KI mice are metformin intolerant.
To determine whether KI mice exhibited altered responses to an acute dose of metformin, we performed a metformin-tolerance test. As metformin affects intestinal glucose absorption 24 , we intraperitoneally injected glucose (2 g kg -1 ) following an oral administration of 250 mg kg -1 metformin ( Supplementary Fig. 7a ), a dose commonly used in rodents to elicit an acute glucose-lowering effect [7] [8] [9] 25 . In WT mice, prior administration of metformin promoted significantly faster disappearance of blood glucose compared to vehicle-treated control (Fig. 5a ). In contrast, the glucose-lowering effect of metformin was Results are expressed as the pT172-AMPKα /AMPKα ratio normalized to the WT-vehicle group (e). n = 5 mice per group. f,g, Arterial blood glucose (f) and GIR (g) during metformin-euglycemic clamps in WT and KI mice. Mice were fasted for 5 h and infused intravenously with metformin (rate of 3.75 mg kg -1 min -1 ) and a variable infusion of 50% glucose to maintain euglycemia at 120 mg dl -1 over a period of 120 min. *P < 0.05 (WT versus KI). h, Plasma and liver metformin concentrations at the end of the clamp period. i-l, Rates of endogenous glucose production (EndoRa) (i), gluconeogenesis (GNG) (j), glycogenolysis (GYG) (k) and glucose disappearance (Rd) (l) during the resting period (5 h fasted) and steady state of the metformin clamp (average from 100-120 min). Results represent mean ± s.e.m.; n = 8 (WT-resting), 8 or 9 (WT-clamp), 10 (KI-resting) and 9-11 (KI-clamp) mice. *P < 0.05. Statistical significance was determined using an unpaired, two-tailed Student's t-test and an alpha level of 0.05.
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NATure MedICINe markedly lower in KI mice ( Fig. 5b ), even though plasma and liver metformin levels (~125-150 μ M and ~0.7 μ mol g -1 , respectively) were comparable between the groups of mice ( Fig. 5c ). Metformin caused a comparable increase in hepatic [AMP]:[ATP] (approximately twofold) and decreased energy charge (~10%) in both groups of mice (Supplementary Table 5 ). This change in energy status was associated with a robust increase in phosphorylation of liver AMPK and ACC ( Fig. 5d,e ).
To further investigate whether KI mice were resistant to the glucose-lowering effect of metformin in vivo, we developed and optimized a 'metformin-euglycemic clamp' protocol in conscious, unrestrained mice ( Supplementary Fig. 7b ). A similar technique has been used previously to assess the effect of metformin on HGP in mice 26 . Two different doses of metformin (1.875 mg kg -1 min -1 and 3.75 mg kg -1 min -1 ) were tested. Metformin was infused intravenously at a constant rate while the glucose infusion rate (GIR) was adjusted to maintain euglycemia ( Fig. 5f ). We observed that the lower dose (1.875 mg kg -1 min -1 ) failed to significantly increase GIR from baseline in WT (and also KI) mice under the euglycemic condition ( Supplementary Fig. 7c,d ), even though metformin had reached ~170 μ M and ~0.8 μ mol g -1 in plasma and liver, respectively ( Supplementary Fig. 7e ). These concentrations were comparable to those observed following an acute oral administration of 250 mg kg -1 (Fig. 5c ). This is likely due to differences in the route of administration. The first pass of metformin from the gastrointestinal tract, via the portal vein and liver, into systemic circulation is crucial for the glucose-lowering effect. First, administration of metformin via the portal-hepatic pathway produces more profound glucose lowering than direct systemic infusion 27 . Second, it has been proposed that there is also a direct effect of metformin on the gut itself. For example, it has been recently suggested that metformin reduces HGP through a gut-brain-liver neuronal network via activation of AMPK in the duodenum, resulting in release of GLP-1 (ref. 28 ). Another study has shown that metformin reshapes the gut microbiota through interacting with different bacteria, possibly via metal homeostasis 29 . ; n = 10-12 mice per group. eq., equivalent. g,h, After 10 weeks of dietary intervention, WT (g) and KI (h) mice were fasted for 16 h, administered vehicle (water) or metformin (250 mg kg -1 p.o.), and blood glucose was measured after 2 h. n = 13 (WT-vehicle), 15 (WT-metformin), 8 (KI-vehicle) and 12 (KI-metformin) mice. *P < 0.05 (vehicle versus metformin). #P < 0.05 (resting versus 120 min). i-k, After 12 weeks of dietary intervention, mice were fasted for 16 h and administered vehicle (water) or metformin (250 mg kg -1 p.o.), and liver biopsies were taken after 2 h of drug treatment. Liver metformin (i), pT172-AMPKα phosphorylation (expressed as pT172-AMPKα /AMPKα ratio normalized to the WT-vehicle group) (j) and cAMP (k) are shown. n = 6 or 7 (WT-vehicle), 6 (WT-metformin), 6 or 7 (KI-vehicle) and 6 (KI-metformin) mice; *P < 0.05 (vehicle versus metformin). # P < 0.05 (WT versus KI). Statistical significance was determined using the unpaired, two-tailed Student's t-test and an alpha level of 0.05.
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Infusion of a higher dose of metformin (3.75 mg kg -1 min -1 ) resulted in a substantial increase in GIR, leading to steady state by the end of the 120-min clamp in WT mice (Fig. 5g) . In contrast, KI mice displayed only a modest increase in GIR (Fig. 5g) , even though plasma, liver and muscle metformin as well as plasma insulin concentrations were similar between the groups of mice ( Fig. 5h and Supplementary Fig. 7f,g) . Combining the metformin-euglycemic clamp with administration of 2 H stable isotope tracers enabled the quantification of endogenous glucose production (EndoRa), including the relative contribution of glycogenolysis and gluconeogenesis. EndoRa was significantly suppressed (~20%) in WT mice during the clamp (Fig. 5i ). This was due to reduction of both gluconeogenesis and glycogenolysis (Fig. 5j,k) . In contrast, metformin-induced suppression of EndoRa, gluconeogenesis and glycogenolysis was ablated in KI mice ( Fig. 5i-k) . Overall, the clamp study revealed that KI mice were largely insensitive to the glucose-lowering effect of metformin because of ablation of metformin-induced suppression of HGP. However, it should be noted that owing to the systemic route of delivery (as mentioned above), much higher and suprapharmacological doses were needed to elicit a robust glucose-lowering effect, resulting in an artificially higher glucose disposal rate (~40-50% increase in both WT and KI) than is seen at therapeutic doses (Fig. 5l ). It has been shown that metformin can stimulate glucose uptake in isolated rat skeletal muscle at suprapharmacological doses (but not at clinical doses due to the absence of OCT1 (ref. 30 )) by activating AMPK 5 , which could sensitize insulin action and further promote glucose uptake in muscle 31 . In support of this premise, metformin concentration in skeletal muscle was increased twofold when infused at the higher rate (3.75 mg kg -1 min -1 ) compared to the lower rate (1.875 mg kg -1 min -1 ) ( Supplementary Fig.  7g ). The molecular basis underlying reduced glycogenolysis in WT mice during the clamp is unknown, as we observed no significant difference in the levels of phosphorylation or activity of glycogen synthase (GS) and glycogen phosphorylase (GPa) as well as hepatic glycogen content between groups of mice at the end of the clamp ( Supplementary Fig. 7h-m) . We monitored tissue distribution and pharmacokinetics of metformin delivered via the systemic route and performed positron emission tomography (PET) analysis following an acute intravenous infusion of [ 11 C]metformin. We found that the kinetics and total metformin uptake in liver was comparable between WT and KI mice ( Supplementary Fig. 8 ), consistent with the snapshot measurements of hepatic metformin concentration as shown in Fig. 5c and Supplementary Fig. 7e . In addition, PET analysis highlighted a rapid and marked accumulation of metformin in the bladder, corroborating the need for a much higher dose to achieve a glucose-lowering effect via the systemic route than the gastrointestinal route.
FBP1-G27P-KI mice are resistant to the acute hypoglycemic action of metformin in an obesity-induced model of diabetes.
We next assessed whether KI mice were resistant to the glucoselowering effect of metformin under the hyperglycemic (diabetic) condition. WT and KI mice were fed a high-fat diet (HFD) for 10 weeks, and both groups of mice had similar profiles of weight gain and food intake over the period of dietary intervention (Fig. 6a,b ). HFD-fed WT and KI mice showed hallmark features of type 2 diabetes, including glucose intolerance, hyperglycemia, hyperinsulinemia as well as hypertriglyceridemia ( Fig. 6c-f ). At the end of HFD intervention, we orally treated WT and KI mice with metformin (250 mg kg -1 ) or vehicle (water) and monitored blood glucose levels 2 h following metformin treatment. We found that metformin, but not vehicle, produced a significant reduction of blood glucose levels in WT mice (~30-40%), but the effect was significantly blunted in KI mice (P = 0.047; Fig. 6g,h) . We verified that hepatic metformin levels (Fig. 6i ) and the magnitude of changes in [AMP]:[ATP] and energy charge ( Supplementary Table 6 ) as well as associated increases in AMPK phosphorylation (Fig. 6j) were comparable between genotypes. Inhibition of gluconeogenesis by metformin in WT mice could also be supported by a modest fall in hepatic glucose and G6P levels, which was blunted in KI mice. Similarly, inhibition of the step catalyzed by FBP1 was suggested by a decrease in F6P (P = 0.053) and a concomitant increase in F-1,6-P 2 in livers from metformin-treated mice (P = 0.091) that was lower in KI mice ( Supplementary Table 7 ). However, given that there was a modest (~10%) but significant effect of decreased blood glucose following metformin treatment in KI mice (Fig. 6h) , there must be additional mechanisms, independent of AMP-mediated FBP1 inhibition, to lower blood glucose. This is unsurprising given that metformin has multiple proposed primary and secondary targets 1 , including mitochondrial complex I 2-4 and glycerol-3-phosphate dehydrogenase 10 in the liver, as well as duodenal AMPK 28 . Although it has been proposed that one of the mechanisms of action of metformin involves a reduction in hepatic cAMP 9 (a key mediator of glucagon signaling), there was no significant effect ( Fig. 6k ) and an actual increase in downstream phosphorylation of PKA substrates (i.e., pS33-PFKFB1 and pS133-cAMP response element-binding protein (CREB)) ( Supplementary Fig. 9a,b ) under the conditions of our model system (it has been reported that the reduction in cAMP is only apparent at substantially higher dose (i.e., 400 mg kg -1 ) 7 ), although we cannot rule out the possibility that we have missed the time point at which cAMP-PKA signaling was suppressed following metformin treatment.
Discussion
Metformin has been in use for more than 50 years as an antihyperglycemic agent for the treatment of diabetes. Despite the clinical success of metformin, there is no clear consensus regarding its mode of action, and multiple seemingly contradictory mechanisms have been proposed. However, a common narrative emerges when a clear distinction is drawn between acute versus chronic effects of metformin that can be mediated by either direct or indirect effects on HGP by metabolic or genic means. We have focused specifically on the acute effect of metformin on HGP, where it is clear that AMPK is dispensable. Hepatic AMPK-null mice do not exhibit a defect in either steady-state glycemia, pyruvate tolerance or the acute glucoselowering effect of metformin 8 . Furthermore, treatment of cultured hepatocytes 8 or intravenous infusion of the specific AMPK activator A769662 has no effect on glucose production 10 . Although hepatic LKB1-null mice present with severe hyperglycemia and hyperlipidemia due to upregulation of CREB and peroxisome proliferatoractivated receptor-γ coactivator 1α (PGC1α ) transcriptional targets (Pck1 and G6pc) 32 , recent work suggests that this is due to impaired activity of the AMPK-related kinase, salt-inducible kinase (SIK) 33 , and not AMPK. Much is often made of the short-term changes in Pck1 and G6pc mRNA in response to pharmacological activation of AMPK, but when protein levels are assessed, they are invariably unaltered. Indeed, a poor correlation has been noted between the expression of gluconeogenic genes and HGP 34 . In short, although biguanides can clearly activate AMPK, it is neither sufficient nor necessary for acute inhibition of HGP.
Obesity-induced diabetes is a standard model in rodent studies, and it is generally accepted that the associated hyperglycemia is a consequence of hepatic insulin resistance in fatty livers. It is well established that AMPK is a critical regulator of lipogenesis, and chronic treatment of diabetic mice with metformin profoundly improves glucose tolerance by reducing hepatic steatosis and improving insulin resistance. Of note, mice expressing nonphosphorylatable mutants of ACC1 and ACC2 (ACC1/2-KI), were resistant to the lipid-and glucose-lowering effect of chronic metformin treatment. Notably, the acute hypoglycemic effect of a single dose of metformin was unaffected 7 . The same mechanism likely underpins the glucose-lowering effect of chronic A769662 Articles NATure MedICINe treatment in obese ob/ob mice, in which dramatic reductions in hepatic and plasma lipid were observed 35 . Consequently, AMPK plays a role in the chronic, indirect inhibition of HGP by alleviating hepatic insulin resistance.
Plasma metformin concentration in humans is markedly variable, due in part to the complex pharmacokinetics of the drug and profound intersubject variations in absorption and elimination 36 . It is difficult to quote a meaningful elimination half-life (t ½ ) because the time course of plasma concentrations of metformin follows a multiphasic pattern-however, values in the range from 1.7 to 4.5 h have been reported 36 . Plasma metformin concentration in patients treated with a normally prescribed dose of metformin (1 g, twice per day) has been reported within the range of 0.4-32 μ M (plasma levels obtained 14 h after last drug administration) in 159 subjects with well-regulated type 2 diabetes under controlled conditions 37 . In contrast, plasma metformin levels between 0 and 113 mg l -1 (868 μ M) have been measured in random blood samples from diabetic subjects 38 . Both studies have provided useful information, as the former 37 gives an estimate of nadir during multiple dosing, whereas the latter 38 provides a valuable estimate of the maximum concentration of metformin during clinical use. However, overall it has to-date been a challenge to establish the therapeutic range of metformin concentrations in plasma.
The current debate on metformin has turned toward the issue of the validity of the concentrations and doses used in rodent models. It has long been recognized that the effective hypoglycemic dose exhibits a marked species dependence, and researchers rightly use doses that produce robust, reproducible effects. In this regard, it is difficult to compare studies that have not measured plasma and/ or liver accumulation as the drug formulation, route of administration and degree of fasting will impact the pharmacokinetics. Species differences in OCT1 expression have also been identified; although both rodent and human liver express OCT1, its expression in human intestines appears much lower than in mice 39 . As metformin is administered orally, differences in intestinal OCT1 expression may affect portal vein levels of metformin and thereby hepatic uptake without detectable effects on metformin levels in peripheral veins. In addition, hepatic exposure to the drug depends not only on OCT1, but also on multidrug and toxin extrusion (MATE) isoforms acting as influx and efflux transporters, respectively. Differential hepatic expression of MATE1 between humans and rodents has been reported 40 , which may also affect metformin kinetics. It has been observed that a glucose-lowering effect occurs in response to a single dose of 50 mg kg -1 in rats 10 . However, it should be noted that metformin (50 mg kg -1 ) was given intravenously, which led to plasma metformin concentration of ~74 μ M 30 min after administration, whereas 100 mg kg -1 and 250 mg kg -1 doses increased plasma metformin concentration of 345 μ M and 1,300 μ M, respectively 10 . Further, the study exploring the effect of metformin in ACC1/2-KI mice used a chronic dose of 50 mg kg -1 (i.p.) for 12 weeks; however, a dose of 200 mg kg -1 was needed (50 mg kg -1 had no effect) to observe a glucose-lowering effect in single-dose experiments 7 . Taken together, the dose range of 200-350 mg kg -1 has consistently been used [7] [8] [9] 25 , and indeed, the dose used in our study is similar to the maximum daily human dose (2 g) when allometric scaling is applied (dose for 25 g mouse = 2,000 × (0.025 / 65) 0.75 = 5.5 mg = 220 mg kg -1 ).
With cultured hepatocytes, it is typical to see claims of enhanced justification on the basis of using lower doses but for greatly increased periods of time (often 16-24 h). Given that the uptake of metformin in isolated hepatocytes is relatively slow 2 (in contrast to the rapid uptake in human and rodent livers in vivo 41, 42 ) and potentially antagonized by competing OCT substrates in complex medium 43 , intracellular accumulation is both time-and concentration-dependent, such that higher drug concentrations will reach effective intracellular levels within more relevant time periods. The apparent discrepancy in reported efficacy of metformin on isolated hepatocytes is likely due to the wide range of culture conditions used with respect to media (complex versus balanced salt solutions), carbon sources and hormones. Indeed, under commonly used conditions for glucose production assays in which the sole carbon sources are typically lactate and pyruvate, metformin produces precipitous decreases in intracellular ATP concentration (~85% reduction at 1 mM) that closely follow apparent changes in glucose production or gene expression 8 . Such extremes in adenylate energy charge are not observed in any physiological setting in vivo. Consequently, the lack of standardization in hepatocyte protocols and the ease with which extreme energy deprivation can be induced with metformin renders the many reported results difficult to consolidate.
The final area of controversy concerns the role of changes in adenine nucleotides in metformin action. Several early studies reported activation of AMPK in the apparent absence of increases in AMP concentration 44 , which has been used to argue that metformin does not alter cellular energetics. However, experiments using AMP-resistant AMPKγ 2 mutants have clarified that AMPK activation by metformin and essentially all xenobiotic compounds is mediated by increases in AMP concentration 45 . Technical errors in many contemporary studies have resulted in misleading values reported for hepatic adenine nucleotides ([ATP]:[AMP] « 10, often approaching 1). Hepatic AMP concentration is a very sensitive indicator of stress and increases by ~10-fold within just 30 seconds of hypoxia 18 . Consequently, tissues must be freeze-clamped in situ to enable accurate measurements and reveal subtle changes in energy status. Even then, AMPK can easily be activated by increases in free AMP concentrations that are below the limit of quantification. Consequently, AMPK is a sensitive reporter of subtle changes in [AMP]:[ATP], and pT172-AMPKα is a more reliable indicator of changes in the AMP concentration than technically demanding direct measurements. Hence, it can be argued that a consensus emerges that metformin induces changes in hepatic energy status which is sufficient to modify the activity of sensors such as AMPK and FBP1. Nonetheless, we observed here a modest but significant reduction in energy charge in response to metformin treatment in the liver, which may have partly contributed to suppression of energy-demanding gluconeogenic flux 8 .
Understanding the mechanism through which metformin reduces HGP and normalizes blood glucose levels in hyperglycemic type 2 diabetics is of considerable importance. Our results show that metformin induces a mild energy stress in liver, leading to an increase in AMP concentration that allosterically inhibits FBP1 to lower HGP. This is potentially a powerful mechanism, as the subsequent increase in F-1,6-P 2 will activate PK and increase glycolytic flux 46, 47 . Our study further supports the advancement of FBP1 as a key target for the treatment of type 2 diabetes, either directly using targeted inhibition 48 or indirectly as a consequence of inducing energy stress. The later mechanism may contribute substantially to the apparent glucose-lowering effect of many biologically active secondary metabolites and to new antidiabetic drugs exploiting the emerging concept of mild mitochondrial uncoupling 49 .
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41591-018-0159-7.
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Preparation of rFBP1. 6HIS-FBP1 was expressed in the Fbp-null E. coli strain, DF657(DE3), as described by Giroux et al. 51 . DF657 was sourced from the CGSC (Yale University, CT, USA), and the DE3 lysogen was prepared using the λ DE3 lysogenization kit (Novagen no. 69734). Cells were transformed with pET28a-FBP1 and cultured in minimal medium (M9 salts, 2 mM MgSO 4 , 0.4% (wt/vol) glycerol, 5 μ g ml -1 thiamine-HCl, 0.5% (wt/vol) casamino acids and 50 μ g ml -1 kanamycin) overnight at 37 °C. Minimal medium (0.5-1 l containing 25 μ g ml -1 kanamycin) was inoculated 1:40 with the starter culture and induced with 0.4 mM IPTG at an optical density of 600 nm (OD 600 ) of ~0.4 for 16 h at 37 °C. Cells were lysed in 5 ml g -1 50 mM phosphate pH 7, 150 mM NaCl, 0.5 mM tris(2-carboxyethyl) phosphine (TCEP), 0.2 mM phenylmethylsulfonyl fluoride (PMSF) and 5 μ g ml -1 leupeptin by sonication (1 min, 40% amplitude) and were clarified at 20,000 g for 20 min at 4 °C. 6HIS-FBP1 was batch-bound to Co + -charged IMAC resin (Talon) for 30 min at 4 °C, washed with 10 volumes of lysis buffer, 10 volumes of 5 mM imidazole and eluted with 5 volumes of 150 mM imidazole. Preparations were exchanged into 50 mM imidazole pH 7.4, 0.3 M KCl, 0.2 mM EDTA and 0.5 mM TCEP over Sephadex G-25, concentrated using 10-kD MWCO centrifugal devices (Sartorius Vivaspin) and stored at -20 °C in 50% (vol/vol) glycerol. The presence of imidazole in concentrated solutions of 6HIS-FBP1 was essential to prevent aggregation. Untagged FBP1 was prepared by on-column cleavage of 6HIS-LEVLFQ*GPGS-FBP1 (constructed in pET15 and prepared as described above) with 50 μ g HRV-3C protease per mg 6HIS-FBP1 in 50 mM TES pH 7.4, 150 mM KCl, 0.5 mM TCEP. Preparations were polished over a Superdex 200 10/300GL column equilibrated with 50 mM TES pH 7.4, 0.3 M KCl and 1 mM dithiothreitol (DTT) and stored at -20 °C in 50% (vol/vol) glycerol. Preparations were stable for at least 6 months. As a reference, FBPase was purified from mouse liver essentially as described by Tashima et al. 52 . Briefly, 20 g liver from C57BL/6 N mice was homogenized in four volumes of 20 mM phosphate pH 7, 150 mM KCl, 1 mM EDTA, 1 mM DTT, 0.5 mM PMSF and 2 μ g ml -1 leupeptin and was clarified at 10,000 g for 20 min at 4 °C. The supernatant was subjected to heat denaturation at 60 °C for 1 min and centrifuged at 20,000 g for 20 min at 4 °C. The supernatant was subjected to a 55-75% ammonium sulfate cut, and the resulting pellet was dissolved in 1 mM EDTA and dialyzed overnight against 10 mM sodium malonate pH 6.2, 1 mM EDTA (Buffer A). FBPase was batch-bound to 30 g P11 phosphocellulose, washed with 300 ml Buffer A under suction and transferred to an XK26/20 column. The resin was washed with buffer A containing 50 mM NaCl until absorbance at a wavelength of 280 nm (A 280 ) < 0.01, and FBPase was eluted with 2 mM F-1,6-P 2 and 20 μ M 5′ -AMP. Positive fractions were dialyzed against Buffer A and the pH was adjusted to 5.8 with malonic acid; then, these were applied to a 1.6 × 10 cm column of Blue Sepharose FF (C16/20). The column was washed with 10 mM sodium malonate pH 5.8 and 1 mM EDTA, and elution was performed with 1 mM F-1,6-P 2 and 1 mM AMP. The preparation was polished over a Superdex 200 10/300GL column equilibrated with 20 mM phosphate pH 7, 150 mM KCl and 1 mM EDTA and stored in 50% (vol/vol) glycerol at -20 °C.
FBPase assay. FBP1 activity was determined by monitoring the formation of F6P using a coupled spectrophotometric assay. The specific activity of rFBP1 was determined in 1-ml reactions containing 50 mM TES pH 7.4, 0.2 mM NADP + , 0.1 M KCl, 0.05 mM EDTA, 2 mM (NH 4 ) 2 SO 4 , 2 mM MgCl 2 , 0.05% (wt/vol) BSA, 2 mM 2-mercaptoethanol, 0.8 U/ml phosphoglucose isomerase and 0.5 U ml -1 G6PD. Reactions were started by the addition of 35 µ M F-1,6-P 2 , and A 340 was recorded in a Cary 100 spectrophotometer at 30 °C. Reaction rates were calculated from the linear phase assuming ε (NADPH) = 6.22 mM -1 cm -1 . 1 U is defined as 1 μ mol F6P formed per min at 30 °C. Where appropriate, 1 U/ml AMP deaminase (purified from chicken muscle using P11 phosphocellulose, essentially as described by Smiley et al. 53 ) was included to remove contaminating AMP from NADP + , as described by Han et al. 54 . The activity ratio at pH 7.2 and pH 9.4 was determined under similar conditions in reactions buffered with 50 mM bis-tris propane at the appropriate pH. Other kinetic properties were determined in a 96-well format in nonbinding black microplates (Greiner no. 655900), in which the quantity of NADP + was reduced to 0.15 mM, and reactions were monitored by the increase Articles NATure MedICINe in fluorescence (λ ex = 345 nm, λ em = 465 nm) calibrated by the addition of 5 nmol F6P. K m (F-1,6-P 2 ) was determined at 2 mM Mg 2+ and fitted to equation 1:
(1) Where: V, initial velocity; V 0 , maximum velocity in the absence of inhibitor; I, concentration of inhibitor; I 0.5 , concentration of inhibitor that gives 50% inhibition; and h, hill coefficient.
Stock solutions of F-1,6-P 2 were standardized by enzymatic assay in reactions containing 50 mM imidazole pH 7, 0.15 mM NADH, 0.02 U/ml aldolase, 1.2 U/ml triosephosphate isomerase and 0.16 U/ml glycerol-3-phosphate dehydrogenase. Stock solutions of AMP, 5′ -inosine monophosphate (IMP) and 5′ -AICAR monophosphate (ZMP) were prepared in 20 mM TES pH 7.4, neutralized with NaOH and standardized by ultraviolet (UV) absorbance in 0.1 M phosphate pH 7 at A 259 (ε AMP = 15.4 mM -1 cm -1 ), A 249 (ε IMP = 12 mM -1 cm -1 ) and A 265 (ε ZMP = 12.5 mM -1 cm -1 ), respectively. F-2,6-P 2 is difficult to obtain commercially, and the crude product available from Toronto Research Chemicals was solubilized in 10 mM NaOH and standardized in reactions containing 50 mM HEPES pH 7.1, 5 mM MgCl 2 , 0.1 mM EDTA and 0.15 mM NADP + by sequential addition of 0.1 U/ml G6PD, 0.2 U/ml phosphoglucose isomerase and 0.25 U/ml GST-FBPase-2 P251-N440 while the increase in A 340 was recorded.
Thermal stability assay. The thermal stability assay was performed on untagged FBP1 preparations using a Roche LightCycler 480 II. FBP1 was diluted to 0.2 mg ml -1 in 20 mM HEPES pH 7.4, 100 mM KCl, 1 mM MgCl 2 and the indicated ligands, and 5 × Sypro Orange was added sequentially. Solutions (20 µ l) were dispensed in quadruplicate into 384-well white plates, sealed with optical tape and centrifuged at 200 g for 1 min. Fluorescence (λ ex , 465 nm; λ em , 580 nm; melt factor, 1; quant factor, 10) was monitored while the block temperature was ramped from 20 °C to 95 °C at ~1 °C min -1 (24 acquisitions per °C in continuous mode). The melting temperature (T m ) was determined from the maximum of the first derivative of the raw data using Roche Protein Melting software.
TNP-AMP fluorescence spectroscopy. Titration of 2′ ,3′ -O-trinitrophenyladenosine-5′ -monophosphate (TNP-AMP) was performed as described by Nelson et al. 55 using 1 µ M FBP1 in 50 mM tris-acetate pH 7.4, 5 mM F6P, 5 mM P i and 2 mM MgCl 2 at 25 °C. Raw fluorescence (λ ex , 410 nm; λ em , 535 nm) was corrected for dilution and inner-filter effects using equation 4:
Where F corr is the corrected fluorescence, V is the volume at a specific titration point and V 0 is the initial volume. Data were analyzed by nonlinear regression to equation 5: Animals. Animal studies were approved by the local ethics committee, and all protocols were approved by the Service Vétérinaire Cantonal (Lausanne, Switzerland) under license VD2841. C57BL/6NTac FBP1-G27P mice were generated by Taconic Biosciences GmbH as described in Fig. 1d . Animals were kept in a standard temperature-and humidity-controlled environment on a 12-h light and 12-h dark cycle and had free access to water and standard chow or a HFD that was 60% kcal fat (Research Diets Inc. D12492), as described. [ the appropriate sample size was estimated to be 8-10 based on a power calculation assuming α = 0.05, power = 0.8 and variance from previous studies. However, based on pilot experiments, responses to some of the compounds were much larger than anticipated, and fewer animals were required, as indicated in the figure legends. Animals were arbitrarily, but not randomly, assigned to experimental groups, and investigators were not blinded.
Tissue homogenization. Liver biopsies were powdered in a liquid nitrogen-cooled mortar and pestle and homogenized in 10 volumes of extraction buffer using a rotor-stator homogenizer (Polytron, Kinematica AG). For western blotting and assay of G6PC, PK and FBP1, tissues were homogenized in 50 mM tris-HCl pH 7.5, 0.27 M sucrose, 1 mM EDTA, 1% (wt/vol) Triton X-100, 20 mM glycerol-2phosphate, 50 mM NaF, 5 mM Na 4 P 2 O 7 , 0.5 mM PMSF, 1 µ g ml -1 leupeptin, 1 µ g ml -1 pepstatin A, 1 µ g ml -1 aprotinin, 1 µ M microcystin-LR and 1 mM DTT and clarified at 3,500 g for 5 min at 4 °C. Glycerol-2-phosphate was omitted for extracts used for assay of GS and GP. DTT was omitted for extracts prepared for the assay of CS and PC. For GCK, PFK and PEPCK-C assays, tissues were gently homogenized in 50 mM HEPES-KOH pH 7.4, 100 mM KF, 15 mM EGTA, 5% (wt/vol) glycerol, 1 µ g ml -1 leupeptin, 1 µ g ml -1 pepstatin A, 1 µ g ml -1 aprotinin and 5 mM DTT and centrifuged at 100,000 g for 30 min to prepare a cytosolic fraction free of mitochondrial and microsomal fragments. Skeletal muscle biopsies were powdered in a liquid nitrogen-cooled Bessman pulverizer and homogenized in 10 volumes of Triton X-100 extraction buffer supplemented with 50 mM KCl to prevent gelling.
Western blotting. Tissue extracts were denatured in Laemmli buffer at 95 °C for 2 min, fractionated by tris-glycine SDS-PAGE and transferred to PVDF membrane at 100 V for 1 h in Towbin buffer (25 mM tris, 192 mM glycine, 10% (vol/vol) methanol). Membranes were blocked with 5% (wt/vol) skimmed milk in TBS-T (20 mM tris-HCl pH 7.5, 137 mM NaCl, 0.1% (vol/vol) Tween-20) for 1 h at room temperature and incubated in primary antibodies prepared in TBS-T containing 5% (wt/vol) BSA overnight at 4 °C. Membranes were developed using HRP-conjugated secondary antibodies and ECL reagent. For integral membrane proteins (GLUT2, G6PC and G6PT), samples were not boiled but were heated at 37 °C for 30 min. Pyruvate carboxylase was detected using HRP-conjugated streptavidin. OCT1 (SLC22A1) was detected by immunoprecipitation from 200 µ g detergent extracts with 2 µ g anti-OCT1 (Alomone ACT-011) and 5 µ l protein G-sepharose for 2 h at 4 °C. Immune complexes were washed 3 × with 1 ml lysis buffer and eluted with 20 µ l urea-SDS sample buffer (62.5 mM tris-HCl pH 6.8, 2% (wt/vol) SDS, 0.5 mM EDTA, 6 M urea, 0.01% (wt/vol) bromophenol blue and 10% (wt/vol) glycerol) for 1 h at RT. Specificity of detection was confirmed using liver extracts from OCT1-KO mice (provided by Niels Jessen, Aarhus University Hospital, Denmark). Quantitative blotting was performed using detection with either infrared fluorescent secondary antibodies (AF680 and AF790) on nitrocellulose membranes using an Odyssey CLx infrared imaging system (Li-COR) or developed films following ECL detection that were scanned and quantitated by densitometry using ImageJ.
Metabolic phenotyping. Mice were weighed and food consumption was monitored on the same day. Mice were starved for 16 h, starting at 17:00 on the previous day so that all procedures commenced at 09:00 the following morning. Blood glucose was monitored using a glucometer (AlphaTRAK 2, Abbott Logistics B.V.) on venous blood drawn from the tail. Blood lactate was assayed using a meter (Lactate Pro 2, Arkray Inc.). The genotype of experimental animals was confirmed by PCR on 1 µ l blood lysed in 20 µ l 20 mM NaOH, 60% (wt/vol) PEG-200 (ref. 56 ) using KAPA2G polymerase. Glucose tolerance was determined by administration of 2 g kg -1
Articles NATure MedICINe Metformin assay. Metformin was assayed in plasma and tissues by ion-pair reverse-phase chromatography on a Dionex Ultimate-3000 RS HPLC, essentially as described by Zarghi et al. 57 . Plasma was deproteinized with three volumes 80% (vol/vol) acetonitrile containing 5 µ g ml -1 5,5-diphenylhydantoin as internal standard. Protein was pelleted at 10,000 g for 5 min, and the supernatant was used directly. Standards were prepared by spiking metformin (1 mg ml -1 standard prepared in methanol and stored at 4 °C) into drug-free heparinized plasma (Innovative Research Inc. no. IMS-C57BL6-N) so that the final concentration after solvent extraction ranged from 0.3 to 5 µ g ml -1 . Tissue samples were powdered in a liquid nitrogen-cooled mortar and pestle and were homogenized with 10 volumes 10 mM NaOH using a bead mill (Qiagen TissueLyser II, 2 × 2 min at 30 Hz), and 100 µ l was extracted with 1 ml 1:1 acetonitrile:methanol containing 5 µ g ml -1 5,5-diphenylhydantoin. Samples were centrifuged at 16,000 g for 10 min, and 0.3 ml supernatant was evaporated in a Speedvac at 45 °C. The residue was dissolved in 100-200 µ l 40% (vol/vol) acetonitrile, and particulate material was removed by centrifugation before analysis. Standards were prepared by spiking metformin into alkaline tissue extracts from drug-free animals so that the final concentration ranged from 0. Metformin-euglycemic clamp. Prior to the onset of the study an estimation of the required sample size was determined according to:
where the level of significance was α = 0.05 and desired power was 1 --β = 0.8. The quantities z α/2 and z 1−β are critical values from the normal distribution being 1.96 and 0.8416, respectively. The sampled s.d., s, has a value of 2 mg kg -1 min -1 . This value was derived from initial studies in our laboratory using stable isotopes to quantify in vivo EndoRa in fasted mice. δ (2 mg kg −1 min −1 ), which represents the difference we aimed to identify for EndoRa. As such, the resulting sample size rounded off at n = 8. Experimenters were blinded to the genotype until the conclusion of the study. Values were excluded from the reported means on the basis of the following predetermined exclusion criteria:
1. Following completion of metformin clamps for all mice designated for study, the GIRs were assessed. Any mouse that displayed a GIR outlier during the steady state-sampling period (100-120 min) was removed from any further analysis. Outliers were designated as those with values ± 1.5 s.d. from the group mean of a specific time point.
Estimated glucose fluxes (EndoRa, Rd, gluconeogenesis and glycogenolysis)
were excluded from reported means if the value was ± 2 s.d. from the group mean.
Mice were chronically catheterized approximately 7 d before study, as described previously 60 . Briefly, catheters were implanted in the carotid artery and jugular vein for sampling and infusing, respectively. Animals were housed individually post-surgery and were monitored for distress. Prior to study, mice were within 10% of presurgery weight. On the day of study, mice were placed in bedded containers without food or water at 07:00 (t = -300 min), 5 h before initiation of the clamp. An arterial blood sample (80 μ l) was drawn for evaluating the unlabeled, natural isotopic abundance of glucose after 3 h of fasting (t = -120 min). Subsequently, a bolus of 2 H 2 O (99.9%) was delivered over 25 min to enrich total body water to 4.5%. A [6,6-2 H 2 ]glucose prime (80 mg kg -1 ) was dissolved in the bolus. Following the prime, [6,6-2 H 2 ]glucose was continuously infused (0.8 mg kg -1 min -1 ) for the remainder of the fasting period. An arterial blood sample (110 μ l) was taken to determine basal glucose kinetics, arterial glucose and insulin (t = -5 min). Metformin was delivered as a continuous infusion (1.875 or 3.75 mg kg -1 min -1 ), followed by a variable infusion of 50% dextrose (8% [6,6-2 H 2 ]glucose) to clamp blood glucose levels at 120 mg dl -1 . All infused solutions were prepared in a 4.5% 2 H 2 O-saline solution. Blood glucose was monitored (AccuCheck; Roche Diagnostics, Indianapolis, IN) every 10 min, and donor erythrocytes were infused to maintain hematocrit levels during the study. Three arterial blood samples (~100 μ l each) were obtained during the clamp steady-state period 90 min after metformin infusion was initiated for determination of glucose fluxes as well as arterial glucose, insulin and/or metformin levels. Plasma was stored at − 20 °C until analysis. Mice were rapidly euthanized through cervical dislocation immediately after the final steady-state sample. Tissues were rapidly dissected (within 30 s), freeze-clamped in liquid nitrogen and stored at -80 °C until further analysis.
Preparation of glucose derivatives for GC-MS analysis.
Plasma samples were separated into three aliquots. Each aliquot was derivatized separately to obtain di-O-isopropylidene propionate, aldonitrile pentapropionate and methyloxime pentapropionate derivatives of glucose, as previously described 61, 62 .
GC-MS analysis. For gas chromatography-mass spectrometry (GC-MS) analysis, we employed an Agilent 7890 A gas chromatography system with an HP-5ms capillary column (Agilent J&W Scientific) interfaced with an Agilent 5975 C mass spectrometer, and analysis was executed as previously described 61 with minor modifications. Injection volumes were 1 μ l with purge flow times between 20 and 120 seconds. A custom MATLAB function was used to integrate each derivative peak in order to obtain mass isotopomer distributions (MIDs) for the following ion ranges: aldonitrile, m/z 173-178, 259-264, 284-289, and 370-375; methyloxime, m/z 145-149; di-O-isopropylidene, m/z 301-308. MIDs of each fragment were calculated as the averages of two injections per sample. Root mean square error was determined to provide uncertainty and was calculated by comparing the MIDs of unlabeled glucose samples to the theoretical MIDs obtained from the known abundances of naturally occurring isotopes.
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